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Abstract
We have previously shown that human breast cancer
cells that overexpress erbB-2 are growth factor–
independent. In order to test the contribution of erbB-
2 to this and other transformed phenotypes without the
genetic instability of cancer cells, erbB-2 was overex-
pressed in human mammary epithelial (HME) cells.
ErbB-2–overexpressing HME cells exhibit several
transformed phenotypes including cell surface A4
integrin downregulation and invasiveness. We formu-
lated a model for invasiveness that depends on a cell’s
ability to downregulate A4 integrin. As small G-proteins
play a role in cytoskeleton remodeling and as this is a
likely route for A4 integrin trafficking, we investigated
the role of small G-proteins and their downstream
signals in mediating A4 integrin downregulation and
invasiveness using Rac 1. Dominant -negative Rac 1
blocked erbB-2–mediated invasion and reversed erbB-
2–mediated A4 integrin downregulation. In addition,
constitutively active Rac 1 induced A4 integrin down-
regulation and invasiveness. In erbB-2–overexpressing
and in constitutively active Rac 1–expressing cells, a
p38MAP kinase (p38MAPK) inhibitor blocked invasive-
ness and reversed A4 integrin downregulation. These
data suggest a model in which erbB-2 signaling
activates Rac 1, which, in turn, activates p38MAPK,
leading to the downregulation of A4 integrin. These data
strengthen themodel where loss ofA4 integrin at the cell
surface, leading to reduced A4 integrin binding to
plasma fibronectin, plays a role in erbB-2–mediated
invasiveness.
Neoplasia (2003) 5, 128–134
Keywords: Rac 1, p38MAPK, a4 integrin, invasion, erbB - 2.
Introduction
With breast cancer, as with other cancers, mortality is more
commonly due to metastatic lesions than to primary tumors
[1]. Therefore, understanding the molecular changes that
generate the metastatic behavior of primary cancer cells is
a major area that needs to be addressed in breast cancer.
We have chosen erbB-2–overexpressing human mam-
mary epithelial (HME) cells to study the changes associ-
ated with invasiveness. ErbB-2 overexpression occurs in
about 30% of human breast cancers (HBC) and correlates
with a poor prognosis [2,3 ]. We have shown that HME cells
that overexpress erbB-2 exhibit transformed phenotypes
similar to HBC cells [4–6]. These phenotypes included
invasiveness [5,6 ].
Using a novel assay [7] to study the invasive capacity of
human cancer cells, we have described how specific
interactions between plasma fibronectin (pFn) and Fn
receptors act to influence the invasive capacity of normal
and neoplastic cells. We have found that normal HME cells,
which express both the a4b1 and a5b1 Fn receptors, are not
able to invade naturally occurring basement membranes [sea
urchin embryo extracellular matrix (SU-ECM) membranes]
[5 ]. However, normal cells can be stimulated to invade SU-
ECM membranes by ligand binding to a5b1 integrin in the
absence of a4b1 binding [8]. This can be accomplished by
incubating cells with a peptide fragment of Fn, which contains
the a5b1 binding motif, but not the a4b1 binding site, or by
using serum or full - length pFn in the presence of a4-blocking
antibodies [8]. These findings suggest that signaling from
a4b1 integrin acts to block invasion-stimulatory signals that
result from a5b1 integrin activation. Consistent with this
model, we have found that HBC and HME cells transformed
by the overexpression of erbB-2 are also invasive in the SU-
ECM assay, and that these cells express very low levels of
a4b1 integrin on the cell surface [5]. Interestingly, these
transformed cells express equivalent levels of a4 integrin as
normal cells, but a4b1 is not present at the cell surface [5].
These observations suggest that the signaling pathways
operative in HBC cells result in the altered trafficking of a4b1
integrins in a manner that directly influences invasive
capacity (Figure 1).
We investigated the signaling pathways activated in HBC
cells and erbB-2–transformed HME cells that result in the
downregulation of a4b1 from the cell surface and in the
acquisition of invasive capacity. We found that, while
inhibitors of phosphatidylinositol 30 kinase (PI3K) activity
could block invasion, they did not result in the reexpression of
cell surface a4b1 integrin. However, we did find that a
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constitutively active form of Rac 1 could induce both a4b1 cell
surface downregulation and invasive capacity in HME cells.
Furthermore, a dominant negative form of Rac 1 could block
the invasive capacity of transformed HME cells and induce
the reappearance of a4b1 on the cell surface. Finally,
p38MAP kinase (p38MAPK), which can be activated as a
result of Rac 1 signaling [9,10], was found to be the
proximate mediator of a4b1 cell surface downregulation.
Thus, the results implicate Rac 1 and p38MAPK signaling in
the cell surface downregulation of a4b1 integrin, which plays
a direct role in the acquisition of the invasive phenotype of
HBC cells.
Materials and Methods
Cell Culture
The base medium for H16N2-erbB-2, H16N2-Rac V12,
H16N2erbB-2/Rac N17, and H16N2-PTP (vector-only)
cells was Ham’s F12 medium supplemented with 0.1%
bovine serum albumin, 0.5 g/ml fungizone, 5 g/ml gen-
tamicin, 5 mM ethanolamine, 10 mM HEPES, 5 g/ml
transferrin, 10 M T3, 50 M selenium, and 1 g/ml hydro-
cortisone. H16N2-pTP cell medium was further supple-
mented with 10 ng/ml epidermal growth factor. Cells
infected with retroviral expression vectors were selected in
100 g/ml geneticin (G418) or with 1 g/ml puromycin for
2 weeks. All cell culture reagents were obtained from Sigma
(St. Louis, MO).
Retroviruses and Infection
pTPerbB-2 retrovirus construction was previously des-
cribed [4]. The dominant negative Rac 1 (Rac N17) and
constitutively active Rac 1 (Rac V12) constructs were
generous gifts from Dr. Lilli Petruzelli. These Rac cDNA
are contained in the pRET60 retroviral vector. The Pak virus
constructs were a generous gift from Dr. Surenganie
Dharmawadhane [11]. These cDNA are in pREvTRE retro-
viral vector. The PTEN gene is contained in the pTP2000
bicistronic retroviral vector that we have used previously.
Viruses were packaged as previously described [4] and
incubated with cells in the presence of polybrene overnight.
Antibiotic selection was initiated 24 hours after the end of the
infection process, yielding stably expressing HME cells.
Figure 1.Model for invasion. Normal HME cells express the Fn receptors 41 and 51 integrin on the cell surface and are not able to invade basement membrane
substrates. 41 and 51 integrin bind plasma Fn. 5 integrin can bind the PHSRN sequence in module 9 of plasma Fn, whereas 4 recognizes plasma Fn C-
terminal to the 5 recognition sites. We have shown that HME cells that are binding PHSRN -containing fragments without 4 binding to Fn are able to invade. HBC
cells and erbB -2–overexpressing HME cells have lost the expression of 4 integrin on the cell surface and are able to invade basement membranes. Therefore, the
interaction of plasma Fn with 51 integrin is essential for invasion, and the presence of 41 binding to plasma Fn blocks the Fn - induced invasion signals. Data we
have published elsewhere indicate that 51 signaling goes through MMP-1 to mediate invasion.
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Invasion
Cells were suspended in 0.23% trypsin /EDTA (Catalog
no. 15050-057; Gibco Life Technologies, Grand Island, NY)
and placed on SU-ECM basement membranes with or
without fetal calf serum (FCS), according to established
methods [7], for 4 hours at 378C, the time required to
observe maximal invasion percentages for normal and
metastatic cells (Ref. [7 ] and data not shown). The
percentages of spread and adherent cells were evaluated
in each assay to check viability prior to fixation in 2%
formaldehyde and scored at400magnification using phase
contrast optics. Viability ranged from 90% to 98% in all
assays. Mean invasion percentages resulted from at least
two independent determinations involving the scoring of all
cells in contact with the invasion substrates. Each determi-
nation was performed in duplicate. LY294002 (Catalog no.
L-9908; Sigma) stock solution was 25 mM in 100% ethanol.
LY294002 was added to fresh cell media to a final
concentration of 25 M for 24 hours prior to the start of the
assay. A 10 mM stock solution of PD98059 (Catalog no.
513000; Calbiochem, San Diego, CA) was made in 100%
ethanol. PD98059 was added to a final concentration of
10 M for 24 hours prior to the start of the assay. A 10 mM
stock of SRC inhibitor (PD0173952; a gift from Pfizer, Ann
Arbor, MI) was made in 100% ethanol. The SRC inhibitor
was added to a final concentration of 1 M for 24 hours prior
to the start of the assay. Ten-millimolar stock solutions of
SB202190, SB203580, or p38MAPK inhibitor (Catalog nos.
559388, 559389, and 506126; Calbiochem) were made in
100% ethanol. Ten-micromolar SB202190, SB203580, or
p38MAPK inhibitor was added for 24 hours prior to the start
of the assay. CI-1033 (a gift from Pfizer ) in ethanol was
added at 1 M for 24 hours prior to the start of an assay; 10 l
of 100% ethanol was added to an identical plate as a control.
Fluorescence-Activated Cell Sorting (FACS) Analysis
Cells were grown on tissue culture plastic for at least
2 days. Cells were then washed twice in phosphate-buffered
saline (PBS), removed from the dish with 10 mM EDTA, pH
8.0, in 1 Hank’s balanced salt solution, then incubated with
FITC-conjugated anti - integrin a4 integrin antibody (Catalog
no. MAB1382F; Chemicon International, Temecula, CA) for
1 hour at 378C. After washing twice in PBS, the cells were
fixed in 70% EtOH and subjected to FACS. Each cell type
was analyzed in at least two other experiments.
Protein Blots
Cells were lysed in a buffer containing 20 mM Tris–HCl,
pH 8.0, 137 mM NaCl, 1% NP-40, 10% glycerol, 1 mM
Na3VO4, 1 mM PMSF, 1% aprotinin, and 20 g/ml leupeptin.
Protein concentrations were equalized using the Lowry
method. For whole cell lysates, Laemmli sample buffer was
added and the samples were boiled. Equal amounts of
protein were separated by SDS-PAGE. The proteins were
blotted to PVDF membranes and probed with a -PTEN
antibody (Catalog no. sc-9145; Santa Cruz Biotechnology,
Santa Cruz, CA) or a -Rac 1 antibody (Catalog no. R56220;
Transduction Laboratories, Lexington, KY). Each protein
blot was repeated in two independent experiments.
Results
We have demonstrated that the downregulation of cell
surface a4 integrin is required for erbB-2–transformed
HME cells and HBC cells to invade naturally occurring
basement membranes [5,8]; however, we did not determine
the erbB-2–triggered signal transduction pathway that
mediates this phenomenon. In order to elucidate the signal
transduction events that lead to a4 integrin downregulation,
cell surface a4 integrin expression was assessed using
nonpermeabilized cells that were incubated with a FITC-
labeled anti -a4 integrin antibody and analyzed by FACS.
Using this procedure in combination with a 24-hour incu-
bation with CI-1033, an erbB-2 kinase inhibitor [12,13], we
found that the a4 integrin downregulation from the cell
Table 1. Cell Surface a4 Integrin Expression.*
Cell Line a4 Expression
y
PTP 22.3
erbB -2 9.8
erbB -2+EtOH 8.7
erbB -2+CI - 1033 25.5
CI - 1033 is an EGFR family kinase inhibitor
erbB -2+LY294002 11.0
LY294002 is a PI3K inhibitor
erbB -2 /PTEN WT 12.0
erbB -2+PD98059 9.4
PD98059 is a MEK inhibitor
erbB -2+PD173952 5.0
PD173952 is a SRC inhibitor
*As determined by FACS analysis.
yPercent positive cells.
Figure 2. Invasion induced by erbB -2 is inhibited by a variety of pathways.
ErbB -2–overexpressing cells were incubated for 24 hours with 1 M of the
pan -erbB inhibitor CI -1033, 10 M of the MEK inhibitor PD98059, 25 M of
the PI3K inhibitor LY294002, or 1 M of the Src inhibitor PD173952, then
subjected to SU-ECM invasion assays. Invasion percentages are relative to
the invasion capacity of untreated erbB -2 cells. Each assay was performed in
duplicate and repeated at least twice.
130 A4 Downregulation and Invasion Woods Ignatoski et al.
Neoplasia . Vol. 5, No. 2, 2003
surface in erbB-2–overexpressing cells was fully reversible
and dependent on erbB-2 kinase activity (Table 1). Using
the same incubation times, we also found that erbB-2–
mediated invasion was inhibited by CI-1033 by subjecting
the cells to Su-ECM invasion assays (Figure 2).
As erbB-2–mediated invasion was dependent on PI3K
[5], we investigated whether or not PI3K or its downstream
effector molecules could reverse a4 integrin downregulation.
The data in Figure 2 and Table 1 show that inhibitors of PI3K
(LY294002 and in Ref. [5 ] ) blocked invasion but failed to
result in the reappearance of a4 integrin on the cell surface.
Therefore, we investigated other molecules that have been
shown to be involved in erbB-2 signaling for their role in a4
integrin trafficking. Table 1 shows that inhibitors of MEK
(PD98059) or Src (PD173952) also did not result in the
reappearance of a4 integrin on the cell surface, but were able
to block invasion (Figure 2). Based on these observations,
we concluded that trafficking of a4 integrin from the cell
surface is not mediated by PI3K-, MAPK-, or Src-activated
pathways.
As actin reorganization can be facilitated by small G-
proteins [14,15] and actin filaments have been linked to
integrins [16,17], we hypothesized that small G-proteins
could mediate the trafficking of a4 integrin from the cell
surface and affect invasion. As a first step in the analysis of
the role of small G-proteins in the invasive phenotype of
HBC cells and oncogene- transformed HME cells, we
examined the ability of constitutively active Rac 1 to induce
an invasive phenotype in immortalized HME cells, and the
ability of dominant negative Rac 1 to block invasiveness in
erbB-2–overexpressing HME cells. We stably expressed
either Rac V12 (constitutively active Rac 1) or Rac N17
(dominant negative Rac 1) in HME cells using retroviral
expression vectors. Figure 3A shows the expression of the
exogenous Rac V12 in the transduced cells. The data in
Figure 3B demonstrate that small G-proteins play a central
role in the invasive phenotype of oncogene- transformed
HME cells. Not only was Rac V12 able to confer full invasive
capacity on the HME cells, but erbB-2–overexpressing
cells lost invasive capacity after transduction with Rac N17
(Figure 3B ).
Relative levels of cell surface a4 integrin were measured
in cells expressing erbB-2 or Rac 1 mutants using FACS.
Consistent with the observation that Rac 1 can induce
invasion in HME cells, Table 2 shows that expression of Rac
V12 induced cell surface a4 integrin downregulation.
Furthermore, expression of Rac N17 in erbB-2–over-
expressing cells elevated the levels of a4 integrin on the cell
surface, reversing erbB-2–mediated a4 downregulation
(Table 2). Thus, these results not only implicate activation
of small G-proteins in the invasive phenotype exhibited by
erbB-2–overexpressing HME cells, they indicate that small
G-protein–mediated pathways are involved in the loss of
cell surface a4 integrin, which is essential for the invasive
phenotype.
To further explore whether Rac 1 signaling plays a role in
a4 integrin downregulation and invasion, we utilized two PAK
constructs. PAK is a serine/ threonine kinase that binds to
activated Rac 1 [9]. One PAK construct contained the PAK
autoinhibitory domain that interacts in trans with the catalytic
domain to specifically block PAK phosphorylation of exog-
enous substrates (PAK 83–149). The second construct has
a mutation in the same domain so that it no longer binds to
PAK (PAK 83–149/L107F) [11,18,19]. We expressed
these constructs independently in erbB-2–overexpressing
cells, and tested them for invasive capacity. Figure 3B shows
that only the PAK 83–149 construct could block erbB-2–
Figure 3. Rac 1 facilitates erbB -2–mediated invasion. H16N2 cells were
infected with retroviral expression vectors containing Rac and PAK constructs.
Proteins from whole cell lysates were separated on 10% SDS-PAGE and
blotted to PVDF membrane. (A ) To validate expression of Rac V12,
immunoblots were prepared and probed with an anti –Rac 1 antibody.
Endogenous and exogenous Rac 1 are indicated. (B ) Constitutively active
Rac 1 (Rac V12 )–expressing cells, dominant negative Rac 1 (Rac N17 )–
expressing erbB -2 cells, or erbB -2–overexpressing cells containing the
dominantly acting PAK construct (PAK 83–149 ) or a control construct (PAK
83–149 /L107F ) were subjected to SU-ECM invasion assays. Invasion
percentages are relative to the invasion capacity of untreated erbB -2 cells.
Each assay was performed in duplicate and repeated at least twice.
Table 2. Cell Surface a4 Integrin Expression.*
Cell Line a4 Expression
y
PTP 22.3
erbB -2 9.8
erbB -2+EtOH 8.7
erbB -2+SB202190 21.2
SB202190 is a p38 MAPK inhibitor
Rac V12 11.4
Rac V12 is a constitutively active form of Rac 1
Rac V12+SB202190 22.0
SB202190 is a p38MAPK inhibitor
Rac N17 21.0
Rac N17 is a dominant negative form of Rac 1
*As determined by FACS analysis.
yPercent positive cells.
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mediated invasion, whereas the PAK mutant domain was
without effect. These results indicate that PAK is involved in
erbB-2–mediated invasion.
These results demonstrate that activation of small G-
proteins can play an important role in the acquisition of
invasive capacity in transformed HME cells, and suggest that
Rac 1 is the downstream G-protein responsible for a4
integrin downregulation in erbB-2–overexpressing cells.
However, these results do not rule out the involvement of
other small G-proteins such as CDC 42 that also bind to and
activate PAK.
Activation of p38MAPK leads to cytoskeleton reorganiza-
tion [20,21] and is downstream of Rac 1 [9,10]. p38MAPK
has also been shown to play a role in upregulating matrix
metalloproteinase (MMP) production, which regulates inva-
sion [22,23]. Therefore, we utilized the p38MAPK inhibitor,
SB202190, to determine if p38MAPK played a role in a4
integrin downregulation and invasion. ErbB-2–overexpress-
ing and Rac V12–expressing HME cells were incubated with
10 M SB202190 for 24 hours, and then assayed for cell
surface a4 integrin and for invasiveness. SB202190 expo-
sure induced the reexpression of a4 integrin on the cell
surface of erbB-2–overexpressing or Rac V12–expressing
cells to levels seen in vector control cells (Table 2) without
changing the total amount of a4 in the cells (data not shown).
In addition, Figure 4 shows that SB202190 blocked the
invasive capacity of erbB-2–overexpressing cells, Rac
V12–expressing cells, and the SUM-52 HBC cell line.
Similar results were obtained with 10 M of two other
p38MAPK inhibitors, SB203580, and a separate p38MAPK
inhibitor available from Calbiochem (data not shown). These
results link Rac 1 signaling pathways, involving the activation
of p38MAPK, to the trafficking of a4 integrin away from the
cell surface and, subsequently, to invasion.
As we have shown that erbB-2–mediated invasion is
dependent on PI3K and as there is evidence that PI3K and
Rac 1 can activate each other [24–30], we wanted to
determine if PI3K signaling was required for invasion in Rac
V12–expressing cells. Figure 5 shows that cells expressing
constitutively active Rac do not invade SU-ECM substrates
in the presence of LY294002. Rac V12–expressing cells
also do not invade if they are infected with a retroviral vector
containing wild- type PTEN (Figure 5). These findings
indicate that Rac 1 is not downstream of PI3K in the
signaling required for invasion. It is possible that Rac V12
itself activates PI3K, which, when blocked, also inhibits
invasion. It is also likely that Rac 1 and PI3K, once activated,
stimulate separate pathways that are both required for
invasion. Thus, it is likely that multiple pathways are required
for invasion and there is likely to be significant cross- talk
between these pathways.
In summary, the results presented here implicate Rac 1
signalling, through PAK and p38MAPK, in a4 integrin
downregulation and suggest that a4 integrin downregulation
plays an important role in the invasive phenotype mediated
by the overexpression of erbB-2.
Discussion
The correlation between erbB-2 overexpression and a poor
outcome in HBC has been known for some time [2,3 ].
However, the phenotypes mediated by the increase in erbB-
2 activity have been difficult to determine due to the inherent
genomic instability of cancer cells. To circumvent the
problems associated with the genetic changes in HBC cells,
we have overexpressed erbB-2 in HME cells to levels seen
in breast cancers that demonstrate amplification and over-
expression of erbB-2 [4]. Due to the overexpression of
Figure 4. Invasiveness is dependent on p38MAPK. SUM-52PE human
breast cancer cells, ErbB -2–overexpressing HME cells, and Rac V12–
expressing cells were exposed for 24 hours to 10 M SB202190, then were
subjected to SU-ECM invasion assays. Invasion percentages are relative to
the invasion capacity of untreated erbB -2 cells. Each assay was performed in
duplicate and repeated at least twice.
Figure 5. Rac 1–mediated invasiveness is dependent on PI3K. (A ) To
confirm expression of exogenous PTEN in transduced cells, immunoblots
were prepared and probed with anti -PTEN antibody. (B ) SU-ECM invasion
assay of Rac V12–expressing cells, Rac V12–expressing cells exposed to 25
M LY294002, or Rac V12–expressing cells containing exogenous PTEN.
Invasion percentages are relative to the invasion capacity of untreated Rac
V12 cells. Each assay was performed in duplicate and repeated at least twice.
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erbB-2, these cells are growth factor– independent, anchor-
age- independent, motile, and invasive [4–6]. To determine
how erbB-2 mediates these phenotypes, we investigated
erbB-2– induced signaling pathways and their roles in
mediating these phenotypes.
We have developed a model for the acquisition of invasive
capacity by HBC cells [5,8] (Figure 1). Normal HME cells
bind pFn with both a4b1 and a5b1 integrins. Normal cells can
be induced to invade using only the a5b1 binding site in pFN,
as long as there is no binding to a4b1 by pFn. This indicates
that cell surface a4b1 integrin, when it is bound to pFn, blocks
the invasion signal initiated by the binding of a5b1 to pFn. We
previously found that HBC cells, as well as erbB-2–
overexpressing HME cells, had a decrease in cell surface
a4 integrin but not a decrease in the overall level of a4
integrin [5 ]. These data are suggestive of a trafficking
phenomenon in tumor and transformed cells that correlate
with invasiveness. According to our model, loss of a4 integrin
from the cell surface facilitates the invasive phenotype by
alleviating the block of invasion induced by a4b1 integrin
binding to pFn. This hypothesis was tested in several ways
and on different cancer and normal cell types and was found
to be a common mechanism by which cells regulate
invasiveness [7,8,31]. Supporting this model, Qian et al.
[32] found that the overexpression of a4 integrin in
melanoma cells inhibited invasion.
We have previously shown that erbB-2–mediated inva-
siveness is dependent on PI3K [5]. Here we show that PI3K
signaling pathways do not play a role in cell surface a4
integrin downregulation (Table 1). These data implicate
another erbB-2– induced signaling pathway in a4 integrin
downregulation. As small G-proteins are involved in
rearrangement of the actin cytoskeleton [14,15] and the
cytoskeleton is linked to integrins [16,17], we hypothesized
that erbB-2 mediates a4 integrin downregulation by activat-
ing small G-proteins and their signaling pathways.
Constitutively active and dominant negative mutants of
Rac 1 were used to test this hypothesis. The data obtained
with inhibitors of downstream effector targets of Rac 1 and
with the constitutively active Rac 1 mutant correlated with the
data obtained using the same inhibitors and a dominant
negative Rac 1 mutant in erbB-2–overexpressing cells
(Figure 3 and Table 2). The findings suggest that Rac 1 is in
the erbB-2 pathway and that it mediates a4 integrin
downregulation and, subsequently, invasion.
The findings also indicate that erbB-2, signaling through
Rac 1 to p38MAPK, causes a4 integrin trafficking away from
the cell surface (Figure 4 and Table 2). Interestingly, we did
not find that the overall levels of p38MAPK enzymatic activity
were significantly elevated in erbB-2– or Rac-expressing
cells compared to control cells (not shown). However,
whereas control cells did require the presence of exogenous
growth factors to maintain p38MAPK activity, this enzyme
was active in a growth factor– independent manner in erbB-
2– and Rac V12–expressing cells. These findings suggest
qualitative, rather than quantitative, alterations in p38MAPK
signaling in the downregulation of a4 integrin that takes place
in transformed cells and not in normal HME cells.
Given that our model for invasion implicates signals that
cause a4 integrin retrafficking in invasion, the finding that a
protein that plays a role in cytoskeletal reorganization causes
a4 integrin to be trafficked away from the cell surface is not
surprising. What is perhaps surprising is that Rac 1–
mediated invasion was also dependent on PI3K signaling
(Figure 5) because the main mechanism by which Rac 1
mediates invasion in erbB-2–overexpressing cells is by a4
integrin downregulation, and we demonstrated that PI3K
does not play a role in this phenotype (Table 1). These
observations suggest that Rac 1 is capable of altering
integrin trafficking as well as activating PI3K signaling, which
results in full invasive capacity. There is evidence to indicate
that, under certain conditions, Rac 1 can activate PI3K
activity and signaling [26–30]. However, it is also clear that,
regardless of their mechanisms of activation, Rac 1 and PI3K
activate separate pathways, both of which are required for
invasion. Rac 1–stimulated p38MAPK activation is required
for a4 integrin downregulation, and this is not modulated by
PI3K inhibitors. Similarly, evidence to be published else-
where demonstrates that PI3K signaling activates specific
protein kinase C isoforms that are important in invasive
capacity, and this signaling does not directly involve Rac 1.
In summary, our data indicate that erbB-2 overexpression
in HME cells results in activation of Rac 1 (or another Rac
family member), resulting in the activation of p38MAPK and
the subsequent downregulation of a4 integrin. Invasive capa-
city also requires signaling from PI3K, which does not itself
influence integrin trafficking, but activates other pathways
required for invasion.
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